BACKGROUND: This follow-up study aimed to assess the frequency of late effects on glucose and lipid metabolism after bone-marrow transplantation in childhood. METHODS: 23 long-term survivors (median age 20 years) were studied 3-18 years after bone-marrow transplantation and compared with 23 healthy controls matched for age and sex and with 13 patients in remission from leukaemia. FINDINGS: 12 (52%) of the 23 bone-marrow transplantation patients had insulin resistance, including impaired glucose tolerance in six and type 2 diabetes in four. The core signs of the metabolic syndrome (hyperinsulinaemia and hypertriglyceridaemia combined), were found in nine (39%) of the bone-marrow transplantation patients compared with one (8%) of the 13 leukaemia patients and none of the healthy controls (p=0.0015). The frequency of insulin resistance increased with the time since bone-marrow transplantation. Abdominal obesity, but not overweight, was common among the patients with insulin resistance. INTERPRETATION: Long-term survivors of bone-marrow transplantation are at substantial risk of insulin resistance, impaired glucose tolerance, and type 2 diabetes even at normal weight and young age. They also develop typical signs of the metabolic syndrome. We advocate measurement of serum lipids, fasting blood glucose, and serum insulin for the follow-up of all patients who undergo transplants in childhood, to be continued regularly and possibly life-long.
BACKGROUND: This follow-up study aimed to assess the frequency of late effects on glucose and lipid metabolism after bone-marrow transplantation in childhood. METHODS: 23 long-term survivors (median age 20 years) were studied 3-18 years after bone-marrow transplantation and compared with 23 healthy controls matched for age and sex and with 13 patients in remission from leukaemia. FINDINGS: 12 (52%) of the 23 bone-marrow transplantation patients had insulin resistance, including impaired glucose tolerance in six and type 2 diabetes in four. The core signs of the metabolic syndrome (hyperinsulinaemia and hypertriglyceridaemia combined), were found in nine (39%) of the bone-marrow transplantation patients compared with one (8%) of the 13 leukaemiapatients and none of the healthy controls (p=0.0015). The frequency of insulin resistance increased with the time since bone-marrow transplantation. Abdominal obesity, but not overweight, was common among the patients with insulin resistance. INTERPRETATION: Long-term survivors of bone-marrow transplantation are at substantial risk of insulin resistance, impaired glucose tolerance, and type 2 diabetes even at normal weight and young age. They also develop typical signs of the metabolic syndrome. We advocate measurement of serum lipids, fasting blood glucose, and serum insulin for the follow-up of all patients who undergo transplants in childhood, to be continued regularly and possibly life-long.
Authors: Bradley W Blaser; Haesook T Kim; Edwin P Alyea; Vincent T Ho; Corey Cutler; Philippe Armand; John Koreth; Joseph H Antin; Jorge Plutzky; Robert J Soiffer Journal: Biol Blood Marrow Transplant Date: 2011-08-11 Impact factor: 5.742
Authors: Lori J Bechard; Henry A Feldman; Catherine Gordon; Kathleen Gura; Andrew Sonis; Kathryn Leung; Robert Venick; Eva C Guinan; Christopher Duggan Journal: Contemp Clin Trials Date: 2010-01-03 Impact factor: 2.226
Authors: Can-Lan Sun; John H Kersey; Liton Francisco; Saro H Armenian; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia Journal: Biol Blood Marrow Transplant Date: 2013-04-10 Impact factor: 5.742
Authors: Paul A Hoffmeister; Sangeeta R Hingorani; Barry E Storer; K Scott Baker; Jean E Sanders Journal: Biol Blood Marrow Transplant Date: 2009-12-02 Impact factor: 5.742
Authors: Jean M Mulcahy Levy; Tiffany Tello; Roger Giller; Greta Wilkening; Ralph Quinones; Amy K Keating; Arthur K Liu Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: Chantel Cacciotti; Muhammad Ali; Ute Bartels; Jonathan D Wasserman; Erilda Kapllani; Joerg Krueger; Eric Bouffet; Tal Schechter Journal: Childs Nerv Syst Date: 2020-11-18 Impact factor: 1.475